enGene, Inc. CSO to Present Key Pre-Clinical Data on EG-10 for Treating Inflammatory Bowel Disease
Published: Dec 06, 2010
VANCOUVER, BRITISH COLUMBIA--(Marketwire - December 06, 2010) - enGene Inc., a privately held biotechnology company developing an innovative platform technology to deliver nucleotides (DNA or siRNA) to mucosal tissue for treating a variety of diseases, announced today that Dr. Anthony Cheung, co-founder and Chief Scientific Officer, will give an oral presentation on the Company's compelling pre-clinical data on inflammatory bowel disease (IBD) at the 2010 Advances in IBD - Crohn's & Colitis Foundation's Clinical & Research Conference, being held on December 9-12, 2010 at the Westin Diplomat Hotel in Hollywood, FL.
Dr. Cheung's presentation, entitled, "Successful treatment of experimental colitis by a nanoparticle gene delivery system that localizes expression of interleukin-10 (IL-10) to the colon", will take place at 9:25am, December 11th during the Adaptive Immunity in IBD session.
"The role of IL-10 as a potent anti-inflammatory agent has been well documented in both animal models and human studies," said Dr. Scott Plevy, Assoc. Prof. of Medicine, Microbiology and Immunology at the U. of North Carolina School of Medicine and co-author of the abstract. "A major challenge has always been in the effective delivery of IL-10 - focusing its concentration at the site of disease and minimizing its circulation throughout the body. With this in mind, enGene's technology holds significant promise as a treatment for IBD as well as other gastrointestinal diseases."
More about enGene
enGene Inc. has developed a highly flexible, biopolymer-based nucleotide (DNA and siRNA) delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels. Our platform technology has the ability to significantly impact diseases of mucosal tissues such as the gastrointestinal tract, lung and bladder as well as provide systemic release of proteins from the gut to treat diabetes, anemia, hemophilia and others. The two lead programs are the localized delivery of an anti-inflammatory cytokine, IL-10, for treating Inflammatory Bowel Disease and delivery of insulin in a physiologic, meal-dependent fashion to regulate blood glucose levels. For more information please visit www.engeneinc.com.
Eric A. Adams
President and CEO